Source comparison
CJC-1295 No DAC vs Mod GRF Ipamorelin Blend Explained
The peptide research community uses two names for the same compound. CJC-1295 No DAC and Modified GRF (1-29). Interchangeably, and the confusion drives purchasing mistakes researchers can't afford. Here's what matters: both terms describe sermorelin's modified
This comparison does not assign a generated winner or score.
- The peptide research community uses two names for the same compound. CJC-1295 No DAC and Modified GRF (1-29). Interchangeably, and the confusion drives purchasing mistakes researchers can't afford. Here's what matters: both terms describe sermorelin's modified analogue (amino acids 1–29 of growth hormone-releasing hormone) with four strategic substitutions that extend half-life from eight minutes to approximately 30 minutes. The "No DAC" qualifier exists to distinguish it from the long-acting CJC-1295 WITH DAC (Drug Affinity Complex), which binds to albumin and remains active for 6–8 days. When suppliers list "Mod GRF + Ipamorelin" or "CJC-1295 No DAC + Ipamorelin," they're describing identical peptide blends. The naming convention varies by vendor preference, not molecular structure.
- Our team works with research institutions running growth hormone secretagogue protocols daily. The single most common procurement error is ordering CJC-1295 WITH DAC when the study design requires the short-acting version. The pharmacokinetic mismatch invalidates months of work.
- What's the difference between CJC-1295 No DAC and Mod GRF ipamorelin blends?
- There is no molecular difference. CJC-1295 No DAC and Modified GRF (1-29) are two names for the same peptide sequence. Both pair with ipamorelin to stimulate pulsatile growth hormone release through dual-pathway activation: the GHRH receptor (via CJC/Mod GRF) and the ghrelin receptor (via ipamorelin). The 30-minute half-life of the GHRH analogue synchronises with ipamorelin's 2-hour active window, producing a stronger GH pulse than either compound alone. The "blend" terminology simply indicates both peptides are dosed together in the same injection protocol, typically at a 1:1 ratio.
- The naming inconsistency traces back to early peptide synthesis research. CJC-1295 was the original development name assigned during preclinical testing at ConjuChem Biotechnologies. When the DAC-conjugated long-acting version entered trials, suppliers began appending "No DAC" to the original short-acting sequence to avoid confusion. Meanwhile, academic literature refers to the same compound as Modified GRF (1-29) or Mod GRF, reflecting its structural origin as a modified fragment of endogenous GHRH. Both names describe amino acids 1–29 of growth hormone-releasing hormone with four specific substitutions at positions 2, 8, 15, and 27. Changes that increase enzymatic stability without altering receptor binding affinity. This article covers why the distinction between DAC and No DAC versions matters critically, what the four amino acid modifications actually do, and how ipamorelin's ghrelin-mimetic action compounds the GH release when combined with either naming variant.